Da Qing Cai
Keine laufenden Positionen mehr
Profil
Da Qing Cai served as a Director at Bionano Genomics, Shenogen Pharma Group Ltd., and Berry Genomics Co., Ltd.
from 2016 to 2019.
Currently, he is an Independent Non-Executive Director at Jacobio Pharmaceuticals Group Co., Ltd.
Dr. Cai received his undergraduate degree from the University of Science & Technology of China in 1989, his doctorate from the University of California, Berkeley in 1996, and his graduate degree from Yale University in 1998.
Ehemalige bekannte Positionen von Da Qing Cai
Unternehmen | Position | Ende |
---|---|---|
JACOBIO PHARMACEUTICALS GROUP CO., LTD. | Direktor/Vorstandsmitglied | 23.03.2023 |
BIONANO GENOMICS, INC. | Direktor/Vorstandsmitglied | 01.08.2019 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | Direktor/Vorstandsmitglied | 01.03.2019 |
BERRY GENOMICS CO.,LTD | Direktor/Vorstandsmitglied | 01.04.2018 |
Ausbildung von Da Qing Cai
University of Science & Technology of China | Undergraduate Degree |
Yale University | Graduate Degree |
University of California, Berkeley | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
BERRY GENOMICS CO.,LTD | Health Technology |
JACOBIO PHARMACEUTICALS GROUP CO., LTD. | Health Technology |
BIONANO GENOMICS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | Health Technology |